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Summary A l6Ih-year-old girl with type I glycogen 
storage disease was 'treated by orthotopic 
liver' transplantation under cyclosporinlsteroid 
immunosuppression. All metabolic stigmata of the disease 
were relieved and I year postoperatively she follows a normal 
diet and lifestyle. 
Introduction 
STUDIES of haptoglobin, 1-3 group-specific component,3,4 
and numerous other products of hepatic synthesis5- 9 have 
shown that liver homografts permanently retain their original 
metabolic specificity after transplantation. Consequently, 
liver transplantation has been regarded for some years4 as a 
potentially decisive way to treat those inborn errors of 
metabolism which result partly or completely from defects in 
hepatic function. This objective has been realised in several 
different metabolic disorders.8,9 We report here the first use 
of liver transplantation for the treatment of type I glycogen 
storage disease, a disorder caused by glucose-6-phosphatase 
deficiency . 
Case-report 
The patient was a girl aged l6lh yr whose sibling had died in 
infancy of the same disease. Ai age 2112 yr she had had a prolonged 
hypoglycaemic seizure which resulted in transient blindness, 
hemiparesis, and a residual seizure disorder requiring therapy with 
anticonvulsants. She continued to have recurrent hypoglycaemia, 
acidosis, hyperuricaemia, hyperlipidaemia, abnormal coagulation, 
and epistaxes, and her growth was retarded. After an end-to-side 
portacaval shunt at age 8 yr, 10 all these abnormalities were relieved 
except hypoglycaemia. The frequency of feedings necessary to 
avoid hypoglycaemic symptoms increased from every 4-5 h to every 
2·n. Subsequentlx, overnight nutrient infusions were begun by 
nasogastric tube. I . 
During me 2 yr before transplantation, multiple filling defects in 
her enlarged liver were seen on liver scans, with a dominant lesion in 
Ihe right lobe. These were thought (and were later proved) to be 
slowly growing adenomas, hut the possibility ofa malignant change 
could nO! be ruled out. She had episodes of severe upper abdominal 
pain and liver swclling. In the year before transplantation, she had 
jlUndice with a peak serum bilirubin concentration of 8 mgldl (137 
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mrnoUl) and serum alkaline phosphatase exceeding 3000 IU, 
encephalopathy with blood ammonia levels around 350 jig/dl (206 
jimolll), and persistent increases in serum transaminases. She was 
treated by protein restriction and intermittent intravenous 
alimentation. Her management was complicated by bacterial 
pseudomembranous colitis which was relieved by cholestyramine. 
At the time of transplantation, she was small with normal vital 
signs. Tanner stage III pubertal changes, and tilt typical "potato 
face" of type I disease. She had bilateral right visual· field defects. 
The liver and spleen were palpable IOand6 cm below the right and 
left costal margins. respectively. There was no ascites. Orthotopic 
iransplantation (liver replacement) was done with conventional 
techniques}2 The donor was a 14-year-oid boy of the same blood 
type. Cold ischaemia' of the graft was 5 h. Detachment of the 
portacaval shunt, closure of the resulting defect in the iruerior vena 
cava, and anastomosis of the portal vein to the graft ponal vein were 
not difficult. Biliary reconstruction was with an end-(o-end duct 
anastomosis over a T·tube stent. The T-tube was clamped at 4 wk 
and removed at 7 wk. 
Postoperatively, a small bile leak and right subphrenic 
haematoma necessitated a minor drainage procedure. 
Immunosuppression was with cyclosporin and prednisone.8 After 5 
wk she was discharged on daily doses of 12 mg/lc.g cyclosporinand 15 
mg prednisone. There bas been no evidence of rejection. After I yr, 
the daily cyclosporin dose is 9 mglkg and prednisone has been 
reduced to 5 mglday. 
Results 
The histopathological findings in the native liver, which 
weighed 3400 g, were consistent with type I glycogen storage 
disease. There were multiple hepatic adenomas. Biochemical 
studies of samples quick-frozen at -70°C and stored on dry 
ice were done by Dr Barbara Illingworth Brown, Washington 
University, St Louis. The findings., including absence of 
glucose-6-phosphatase activity, were typical of type I 
glycogen storage disease (table). The glycogen concentration 
in the liver was 8' 7"lo. 
Metabolic investigations were done 6 wk postoperatively. 
The oral glucose tolerance test was normal after 
transplantation, with no hypoglycaemia at 3 h-in contrast to 
the grossly aberrant findings at age 8 yr, just before the 
portacaval shunt (fig. I). At age 8 yr, fasting for a brief period 
caused hypoglycaemia, whereas after transplantation, 
euglycaemia was maintained through a full day offasting (fig. 
2). Postoperatively, in either the fasting or the postprandial 
state, intramuscular injection of glucagon caused plasma 
glucose increments greater than I QOG1o (fig. 3). 
Standard liver function tests have been normal for I yr. 
Serum or plasma concentrations of lactates, lipids, and uric 
acid have been normal. The patient'S lifestyle has been 
transformed. She eats three meals a day. For the first time in 
her life, she can participate in the educational and social 
overnight activities that are pan of normal teenage 
development. 
LIVER ENZYME ACTIVITY OF EXClSED UVER' 
Enzyme 
Glucosc-6-pllO$phalasc 
IkbTllDChing enzyme 
Phosphorylase 
Fruct_ diphosphatasc 
L ysomal • -glucosidase 
Patient 
(jAmol/minig m.er) 
0'08 
0·58 
18·5 
g'l 
2·32 
Controls 
(jAmolJminlgliftr) 
3·7 -14,4 
0,25- 0·75 
12·6 -32'4 
4'2 -15'5 
0'63- 2·85 
• Analyses by Dr Barbara Illingworth Brown. The liver specimen contained 
UDT~ glycogen (normal<5'1'.). Control patienl5 had liver biopsies bcca~ of 
metabolic disorders, heponomcgaly. or railure to IbriYt:. Tbe control ranges 
include or least 10 dilT.r.nt samples. 
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Fig. I-Oral glucose tolerance test al age 8 yr (before portacaval 
shunt) and 6 wlr. afler transplantation. 
I mgldl = O· 055 mmol/1. 
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Fig. 2-Response of blood glucose concentrations during fasting al 
age 8 yr (before portacaval shunl), and 6 wit after liver 
, transplantation. 
Discussion 
Type I glycogen storage disease was the first inborn error of 
metabolism to be classified on the basis of deficiency of a 
specific enzyme, glucose·6·phosphatase. 13 This enzyme is 
found in the liver, kidneys, and intestine. 14 Deficiency of 
glucose·6-phosphatase activity precludes normal breakdown 
of glycogen to glucose and inhibits gluconeogenesis. The 
consequent metabolic disturbances include growth 
retardation, acidosis, lactic acidaemia, hyperlipidaemia, and 
hyperuricaemia. IS Effective treatment for the disease has 
been developed only within the past two deca~esI and our 
patient has participated in each step of this therapeutic 
evolution. The first step was the demonstration that portal-
systemic diversion ameliorated all of the, disease 
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and fed llate, , wlr. after liver transplantatioll. 
manifestations except hypoglycaemia. IO,16 Folkman et al17 
showed that the same benefits could be achieved acutely by 
continuous parenteral alimentation. In an extension of this 
observation, Greene et alII reported such good palliation, 
including control of hypoglycaemia, with round-the-clock 
enteral alimentation that this has become the treatment of 
choice. The.overnight feedings. have usually been by gastric 
tube. 
Liver transplantation is a more specific option, but one 
which has been too dangerous to consider except for life-
threatening complications such as those in our patient. 
However, the criteria for candidacy for this procedure will 
probably become less restrictive in view of the improved 
results with liver replacement that are being reported. I 
Although liver transplantation does not provide glucose-6-
phosphatase directly for the kidneys or intestine, there has 
been no evidence of incompleteness of metabolic correction 
by the normally functioning transplanted liver. 
Tlus ",ork ",as supported by research grants from til<: Veterans 
AdmJOistrauoo; by project grant A.\I. 29961 from the National Institutes of 
Health; and by grant RR 00084 from the General Clinical Research Centers 
Program of til<: Di\"lSlon of Research Resources. NalIonallnstituttS of Health. 
Correspondence shou Id II<: addressed to J. J. .\I.. 
Addendum 
About I yr after transplantation, the patient had an episode of 
melaena. Oesophageal varices were the site of the haemorrhage. 
Superior mesenteric artery angiography and transhepatic 
portography revealed extrahepatic portal vein thrombosis. 
Excellent collatc:ra1 filling of the intrahepatic portal vein and its 
branchc$ was seen, indicating that the homograft still had good 
hepatopetal splanchnic flow. Sclerotherapy controlled the bleeding 
and liver functioos and carbohydrate metabolism continue normal 
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Summary The 'Simplate' technique for measuring 
skin bleeding time was adapted to quantify 
thromboxane A, in the emerging blood as the stable 
degradation product thromboxane B, in twelve Swedish and 
ten English volunteers. During the bleeding time throm-
boxane B, concentrations increased, but as the rate of blood 
loss feII the rate of production of thromboxane A2 was 
constant. The English subjects had shorter bleeding times 
and produced more thromboxane A2 than the Swedish sub-
jects. When the Swedish subjects were grouped according to 
bleeding times those with the shortest had more thromboxane 
A2 than those with longer bleeding times. Clotting venous 
blood in vitro produced much more thromboxane Az than 
bleeding-time blood and there was no correlation with bleed-
ing time. Determination of the opacity of cloning blood to 
form thromboxane Az is therefore irrelevant to in-vivo 
haemostasis. Acetylsalicylic acid greatly diminished the 
appearance of thromboxane Az in the bleeding time and 
prevented the increase ofthromboxane Az concentration with 
time. 
Introduction 
THE extent to which physiological haemostasis depends on 
prostaglandins and related .endogenous agents is still uncer-
tain. Inhibition of prostaglandin biosynthesis by acetylsali-
cylic acid is associated with increases in bleeding time.l-3 
Some familial bleeding tendencies are associated with 
deficiencies in the synthesis ofthromboxane A, by platelets.4 
Neither of these raise bleeding time by more than about 
twice. Studies in human beings given thromboxane-Az-
synthetase inhibitors indicate that haemostasis depends only 
to a minor extent on thromboxane A2.5 
We have alreadY shown that the impairment of human 
haemostasis by acetylsalicylic acid or by a diet enriched with 
fish, both of which diminish prostaglandin formation, occurs 
by different mechanisms.6,7 To determine the contribution of 
thromboxane A2 to primary haemostasis of healthy human 
beings in vivo, we measured thromboxane Az (as its stable 
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metabolite thromboune B2) in blood coming from standard 
incisions made for determining skin bleeding time and the 
thromboxane A2 produced during in-vitro clotting of venous 
blood from the same individuals, determined before and after 
they ingested one dose of acetylsalicylic acid. 
Subjects and Methods 
The subjects were twelve apparently healthy Swedish male 
volunteers (mean age 29±1 SEM years) who had taken DO drugs for 
at least 2 weeks before these investigations. Mter an overnight fast 
for 12 h the bleeding time was determined on one arm. From a 
similar incision OIl the other arm blood was collected for 
thromboxane B2 determinations. Thromboxane B2 was also 
determined in a blood sample from the antecubital vein of that arm. 
A fortnight later the determinations were repeated before and 2 h 
after oral administration of a single dose of acetylsalicylic acid 
(5 mg/kg body-weight). In ten similar English subjects, bleeding 
times and thrombolWle B2 levels in bleeding-time blood were 
determined once in the same way. Bleeding times were determined 
by the same observer in all the subjects. 
Bleeding times were determined with the standard 'Simplate I' 
device (General Diagnostics Inc).8,9 The blood emerging from [he 
skin incision was removed quantitatively every 305 with a disc of 
filter paper (Wharman no I) until bleeding stopped. The bleeding· 
time·blood volumes were measured by eluting tbe spots of blood 
from the filter paper into DflIbkin's solution as previously 
described. 7 In each eluate the haemoglobin concentflltion was 
determined spectrophotometrically and the corresponding blood 
volume obtained from standard curves. The results were expressed 
as,..1 of blood emerging in each 30 s period.. 
Thromboxane Az ronctntflltions in the bleeding-time blood were 
determined by radioimmunoassay of the stable degradation product 
thromboxane B2• The blood emerging from skin incisions made by 
the simplate I device was collected in 1 min periods into capillary 
tubes containing !mown volumes of a mixture of 100 mmolll 
ethylenediamine tem-acetic acid and 5· 59 mmolll indomethacin to 
inhibit in·vitro formation of thromboxane B2. After mixing, the 
tubes were CCatrifu~ at 15 000 g for 2 min. The clear supernatants 
were removed, frozI:n, stored at - 20°C, and assayed later for 
thromboxane B2• The thromboxane B2 standard (U51541 lot 
0071-CLM.()59C) and the antibodies against thromboxane B2 (21) 
were kindly supplied by Dr John Pike of the Upjohn Company, 
Kalamazoo, USA, and Dr John Vane of the Wdlcome Foundation 
Ltd, Beckenbam, UK, respectively. The total amounts of 
thromboxane B2 formed in the bleeding-time blood were calculated 
for each individual by summing the products of the concentflltions 
and the volumes of successive blood samples. Thomboxane B, 
formation was determined also in the serum from blood collected by 
venepuncture into glass tubes in which it was made to clot by 
incubation at 37°C for 1 h. The tubes were centrifu~ at 2000 g for 
10 min, the supernatant sefll sepafllted, frozen, stored at - 20·C, 
and assayed for thromboxane B, by the same procedure. 
The results wue enluated statistically by Student's I test. 
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